Thermo Fisher is entering a collaboration with OpenAI to “help to improve the speed and success of drug development,” the company announced today. Thermo Fisher is embedding OpenAI Application Programming Interfaces (APIs) into product development, service delivery, customer engagement and operational efficiency, the company said. Thermo Fisher said the collaboration will shorten the cycle time…
AstraZeneca breaks ground on potentially $4.5B Virginia plant, adding ADC capacity as tariff fight simmers
AstraZeneca broke ground today on a massive manufacturing complex near Charlottesville, Virginia, which stands to be its largest facility worldwide and a pillar of the company’s $50 billion U.S. R&D and manufacturing plan through 2030. The company intends to ramp up investment and scope of the facility to $4.5 billion, which would eventually create 3,600…
Promise Bio CEO dishes on why Pfizer, AstraZeneca are backing its quest to crack autoimmune trial-and-error
The Tel Aviv startup Promise Bio claims its “color-TV” epiproteomics could slash trial-and-error prescribing for autoimmune disease, an area that already drains more than $100 billion in U.S. health-care spending each year. The company aims to bring a precision medicine approach, which has elevated oncology treatments, to immune-mediated diseases. CEO and co-founder Dr. Ronel Veksler,…
R&D Market Pulse: NVIDIA hits $37.5B in revenue while UK regulators tap brakes on AI startup investment oversight
In a move signaling a more relaxed regulatory approach to the booming AI sector, UK regulators announced they would not investigate Google’s $2 billion investment in AI startup Anthropic. The move mirrors a similar decision regarding Amazon’s earlier $4 billion stake. This green light comes as Amazon doubles, bringing its total investment in Anthropic to…